Additional Information
Level of Instruction: Intermediate
Intended Audience: This course is intended for histology bench technicians and technologists, supervisors, and administrators.
Author Information: Joelle Weaver MAOM, HTL(ASCP), QIHC, is a certified histotechnologist with a broad range of practical histology experience in clinical histopathology. She has received qualification in immunohistochemistry (IHC) from the American Society for Clinical Pathology and Green Belt certification from Purdue University, West Lafayette, Indiana. Joelle's bachelor's degree was received from Bowling Green State University in Bowling Green, Ohio, and her Master's Degree was awarded from Bluffton University in Bluffton, Ohio. She graduated from a NAACLS-accredited histotechnology program and has held positions as an adjunct professor, education coordinator, and program director at Columbus State Community College in Columbus, Ohio (2002-2011). Joelle is a histotechnologist and technical consultant in Louisville, Kentucky, specializing in IHC.
Reviewer Information: Carla J. Shoffeitt, MSM, HT(ASCP), is the Manager of the Pathology Department of Emory St. Joseph’s Hospital of Emory Healthcare in Atlanta, Georgia. She holds a Master of Science in Healthcare Management and a Bachelor of Science in Biology from Troy University, Troy, Alabama. She is certified as a Histotechnician and has 25 years of experience in the field of Histology.
Course Description: Toxicity, side effects, and unpredictable effectiveness have been the hallmarks of anti-cancer therapies used in the past to treat breast and other primary cancers. Targeted therapies have been developed to reduce patient risk and improve patient outcomes. This course will discuss how predictive markers/testing select patients most likely to respond positively to a specific breast cancer treatment, including current testing methodologies and compliance standards.